Pharmacology, Toxicology and Pharmaceutical Science
Fulvestrant
100%
Dacomitinib
86%
Tumor Microenvironment
77%
Immunotherapy
72%
Malignant Neoplasm
72%
Carcinogenesis
66%
Lung Cancer
66%
Lymphocyte Antigen Receptor
66%
Pharmacy Practice
66%
Programmed Death 1 Ligand 1
66%
Oligonucleotide
33%
STAT3 Protein
33%
Epidermal Growth Factor Receptor
33%
Fibronectin
33%
Neoplasm
32%
Lung Adenocarcinoma
26%
Cancer Model
24%
Antiestrogen
21%
Clinical Pharmacy
20%
Tumor Regression
16%
Transcription Factor AP 1
16%
Murine
13%
Adenocarcinoma
13%
Lung Tumor
13%
Protein Tyrosine Kinase
13%
Tumor Antigen
11%
Adenoma
6%
Nitrosamine
6%
Non Small Cell Lung Cancer
6%
Environmental Exposure
6%
Cross-Sectional Study
6%
Programmed Cell Death
5%
Cytotoxicity
5%
Tumor Growth
5%
Immunogenicity
5%
Breast Cancer
5%
Immunosuppressive Agent
5%
Single Chain Fragment Variable Antibody
5%
Medicine and Dentistry
Programmed Death 1 Ligand 1
66%
Fibronectin
66%
Anti-Epidermal Growth Factor Receptor
66%
Non-Small Cell Lung Cancer
66%
Lymphocyte Antigen Receptor
66%
Steroid Hormone
66%
Lung Tumor
33%
STAT3 Protein
33%
Oligonucleotide
33%
Fulvestrant
22%
Dacomitinib
22%
Downregulation
11%
Transcription Factor AP 1
11%
Tumor Regression
11%
Cancer Model
11%
Protein Stability
11%
Cancer Immunotherapy
11%
Single Chain Fragment Variable Antibody
11%
Tumor Antigen
11%
Antiestrogen
11%
Myeloid-Derived Suppressor Cell
6%
Dimer
6%
DNA Binding
6%
4 (Methylnitrosamino) 1 (3 Pyridyl) 1 Butanone
6%
Adenoma
6%
Environmental Exposure
6%
DNA Responsive Element
6%
Binding Site
6%
Nitrosamine
6%
M2 Macrophages
6%
Lung Cancer
6%
Immunosuppressive Treatment
6%
Non Small Cell Lung Cancer
6%
Antigen Expression
5%
